...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vojnosanitetski Pregled >Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients
【24h】

Influence of hemoglobin level and dose of administered recombinant human beta erythropoietin on survival of hemodialysis patients

机译：血红蛋白水平和重组人β促红细胞生成素的剂量对血液透析患者生存的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aim. In patients with end-stage renal disease, treatment with erythropoietin lowers cardiovascular morbidity, improves quality of life and patient survival. The aim of this study was to determine the difference in survival of hemodialysis patients treated with recombinant human beta erythropoietin and patients without this treatment, and to determine the influence of hemoglobin level and erythropoietin dose on the survival of these patients. Method. The study included 291 patients undergoing maintenance hemodialysis, 122 were on erythropoietin therapy, 169 patients formed control group. The study was performed at the Clinic for Nephrology and Clinical Immunology, Clinical Center of Vojvodina, during a 69-month period. We analyzed basic demographic parameters, dialysis duration, underlying disease, comorbidities, death causes, bloodwork parameters and erythropoietin dosage. Descriptive statistics, Anova, Manova, discriminant function analysis, Cox regressional model and Kaplan Meier survival curves were used as statistical methods. Results. Average age and dialysis duration in the experimental group were 47.88 ± 13.32 years, and 45.76 ± 46.73 months, respectively and in the control group 58.73 ± 12.67 years and 62.80 ± 55.23 months, respectively. Average level of hemoglobin and hematocrit in the group in which erythropoietin had been administered was 11.40 ± 8.39 g/dL and 0.35 ± 0.04/L, while the control group these values were 8.52 ± 7.73 g/dL and 0.26 ± 0.04/L, respectively. Average monthly dosage of erythropoietin was 21 587 ± 10 183.36 IJ/month. Significant difference in survival was determined (p 120 g/L), as well as in regard of erythropoietin dose applied ( 40 000 IJ/month). Conclusion. Best survival was noted in patients with hemoglobin > 120 g/L and erythropoietin dose
机译：背景/目标。在患有终末期肾脏疾病的患者中，促红细胞生成素治疗可降低心血管疾病的发病率，提高生活质量和患者生存率。这项研究的目的是确定接受重组人β促红细胞生成素治疗的血液透析患者和未经此治疗的患者的生存率差异，并确定血红蛋白水平和促红细胞生成素剂量对这些患者生存率的影响。方法。该研究包括291例接受维持性血液透析的患者，122例接受促红细胞生成素治疗，169例为对照组。该研究在伏伊伏丁那临床中心的肾脏病和临床免疫学诊所进行了69个月。我们分析了基本的人口统计学参数，透析持续时间，基础疾病，合并症，死亡原因，血液检查参数和促红细胞生成素的剂量。描述性统计，Anova，Manova，判别函数分析，Cox回归模型和Kaplan Meier生存曲线用作统计方法。结果。实验组的平均年龄和透析时间分别为47.88±13.32岁和45.76±46.73个月，对照组为58.73±12.67岁和62.80±55.23个月。服用促红细胞生成素组的血红蛋白和血细胞比容平均水平分别为11.40±8.39 g / dL和0.35±0.04 / L，而对照组则分别为8.52±7.73 g / dL和0.26±0.04 / L 。促红细胞生成素的平均每月剂量为21587±10183.36 IJ /月。确定了存活率的显着差异（p 120 g / L），以及所应用的促红细胞生成素的剂量（40000 IJ /月）。结论。血红蛋白> 120 g / L和促红细胞生成素剂量的患者的最佳生存期

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号